Furthermore, considering that both αvβ6 and αvβ8 have high affinity for the RGD sequence of the TGFβ1 latency-associated peptide (LAP) and participate in the activation of TGFβ (a potent immunosuppressive cytokine) [5, 7, 15] compounds capable of interfering with such interactions may reshape the immunosuppressive microenvironment in tumors and unleash anti-tumor activities. This evidence concerns the gene TGFB1 and neoplasm.